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Abstract
Background: Abnormal expression of the liver peptide hormone hepcidin, a key regulator of iron homeostasis, contributes
to the pathogenesis of anemia in conditions such as inflammatory bowel disease (IBD). Since little is known about the
mechanisms that control hepcidin expression during states of intestinal inflammation, we sought to shed light on this issue
using mouse models.
Methodology/Principal Findings: Hepcidin expression was evaluated in two types of intestinal inflammation caused by
innate immune activation—dextran sulfate sodium (DSS)-induced colitis in wild-type mice and the spontaneous colitis
occurring in T-bet/Rag2-deficient (TRUC) mice. The role of tumor necrosis factor (TNF) a was investigated by in vivo
neutralization, and by treatment of a hepatocyte cell line, as well as mice, with the recombinant cytokine. Expression and
activation of Smad1, a positive regulator of hepcidin transcription, were assessed during colitis and following administration
or neutralization of TNFa. Hepcidin expression progressively decreased with time during DSS colitis, correlating with
changes in systemic iron distribution. TNFa inhibited hepcidin expression in cultured hepatocytes and non-colitic mice,
while TNFa neutralization during DSS colitis increased it. Similar results were obtained in TRUC mice. These effects involved
a TNFa-dependent decrease in Smad1 protein but not mRNA.
Conclusions/Significance: TNFa inhibits hepcidin expression in two distinct types of innate colitis, with down-regulation of
Smad1 protein playing an important role in this process. This inhibitory effect of TNFa may be superseded by other factors
in the context of T cell-mediated colitis given that in the latter form of intestinal inflammation hepcidin is usually up-
regulated.
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Introduction
Inflammatory conditions are often accompanied by a debilitat-
ing anemia known as the anemia of inflammation (AI) [1]. The
pathogenesis of AI is related to abnormally elevated levels of the
liver peptide hormone hepcidin, a key regulator of systemic iron
metabolism [2]. Hepcidin binds to and down-regulates the iron
exporter ferroportin, which is expressed on macrophages and
duodenal enterocytes, thereby inhibiting, respectively, the recy-
cling of iron from erythrocytes and the absorption of iron from the
diet [3]. Thus, elevated circulating hepcidin leads to decreased
serum iron, consequent iron-restricted impairment of erythropoi-
esis and, ultimately, anemia.
Anemia is a common feature of IBD and is multi-factorial in
origin [4]. With the discovery of the role played by hepcidin in AI,
recent investigations have attempted to determine whether this
hormone is involved in the anemia of IBD. The results have not
always been consistent. Urinary hepcidin was found to be
significantly elevated in a study of children with active Crohn’s
disease, correlating with decreased iron absorption from the gut
[5]. An investigation of adults with IBD also demonstrated
elevated serum hepcidin levels in the patients that correlated
positively with disease activity and negatively with hemoglobin [6].
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inactive IBD revealed lower serum hepcidin in patients compared
to controls [7]. The reason for the discordance between the
different clinical studies is not clear. Hepcidin expression has also
been examined in mouse models of colitis. We found that liver
hepcidin expression was up-regulated in the piroxicam/IL-10
knockout colitis model and the Rag knockout/T cell transfer colitis
model [8,9], while other investigators have demonstrated elevated
hepcidin levels in the spontaneous ilietis of TNFDARE mice [10].
Moreover, we showed that reducing hepcidin expression in the T
cell transfer colitis model led to a significant improvement of
serum iron levels, consistent with the idea that elevated hepcidin
contributes to the pathogenesis of the anemia associated with
intestinal inflammation [9].
Hepcidin expression in the liver is regulated exclusively at the
transcriptional level, and is determined by the integration of
multiple signaling inputs acting on several key transcription factors
[11]. Serum iron is a major influence, and is sensed via 2
hepatocyte surface proteins, the hereditary hemochromatosis
protein HFE and the type 2 transferrin receptor, that interact to
activate signals leading to increased hepcidin expression [12–14].
Inflammation is an additional stimulus that up-regulates hepcidin.
IL-6 is an important mediator of this response following injection
of lipopolysaccharide or turpentine, and functions by activating
the transcription factor STAT3 [15–18]. The induction of
hepcidin in response to either inflammatory stimuli or elevated
serum iron is dependent on signals provided by a sub-set of bone
morphogenetic proteins (BMPs). Several BMPs, including BMPs 2,
4 and 6, up-regulate hepcidin in tissue culture systems [19], but
BMP6 is probably the major regulator of hepcidin expression in
vivo [20,21]. Deficiency of BMP6 in mice results in low basal
hepcidin expression, progressive systemic iron overload, and
significantly compromised induction of hepcidin in response to
lipopolysaccharide administration [20,21]. Further supporting the
important role played by BMP-activated signals in controlling
hepcidin expression, we found that neutralization of BMP6, either
alone or together with BMPs 2 and 4, significantly inhibited
hepcidin up-regulation during T cell transfer colitis [9]. Signaling
by BMPs 2, 4 and 6 involves specific type I and type II receptors
and the co-receptor hemojuvelin, and leads to the phosphorylation
of the receptor-associated Smad proteins (Smads 1, 5 and 8),
which then associate with the transcription factor Smad4 to induce
hepcidin expression [22]. Counteracting the signals that increase
hepcidin expression, anemia and hypoxia, as well as decreases in
circulating iron and body iron stores, lead to the down-regulation
of hepcidin expression [11].
The mechanisms that regulate hepcidin expression are complex.
How these mechanisms operate in the context of clinically relevant
inflammation, such as that occurring in IBD, is not well
understood. Shedding light on this issue is important not only
for our basic understanding of how hepcidin expression is
controlled in vivo, but also in terms of clarifying the pathogenesis
of IBD-associated anemia and devising ways to treat this
condition. Accordingly, we carried out experiments to determine
how hepcidin expression is regulated in mouse models of IBD.
Materials and Methods
Ethics statement
All animal studies were carried out in accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Sub-committee on Research Animal
Care of Massachusetts General Hospital (protocol number
2008N000061, animal welfare assurance number A3596-01).
Animal studies
Wild-type, 8 week old female C57BL/6 mice were purchased
from the Jackson Laboratory and were given 3% DSS in their
drinking water for 3 or 7 days. Untreated controls received regular
drinking water. TRUC mice (BALB/c background) and the
characteristics of their intestinal inflammation, have been
described previously [23]. Female TRUC mice and Rag2
knockout controls were used starting at 4 weeks of age. All mice
were maintained under specific pathogen free conditions.
Analysis of hepatic gene expression
After mice were euthanized, pieces of liver were homogenized
in TRIzol reagent (Life Technologies, Grand Island, NY). Total
RNA was prepared and used to determine hepcidin and Smad1
expression by quantitative reverse transcriptase-polymerase chain
reaction (qRT-PCR), essentially as described previously [8].
Relative expression was calculated using the 2
2DDCt method after
normalizing to a housekeeping transcript, GAPDH or actin.
Primers used to amplify hepcidin, Id1, GAPDH and actin have
been published earlier [8,9,21]. Primers for amplification of
Smad1 were: forward, 59GACGCTTTGGTGAA-
GAAACTGA39, reverse, 59ACACGGCAATAAATGACAT-
GAG39.
Serum transaminase estimation
Serum collected from mice at the time of sacrifice was analyzed
for transaminase levels by the Veterinary Clinical Pathology
Laboratory at Massachusetts General Hospital.
Estimation of serum and tissue iron levels
Serum iron was estimated as described previously using a
colorimetric assay kit from Thermo Scientific [9]. Splenic iron was
measured as described previously [19].
Immunoblotting
Liver tissue was homogenized in lysis buffer containing protease
and phosphatase inhibitors as described earlier [8,9]. After gel
electrophoresis and transfer to nitrocellulose membranes, the
lysates were blotted with antibodies to the phosphorylated form of
Smad1/5/8, total Smad1 (Cell Signaling Technology), total Smad
1/5/8 (Abcam), actin or GAPDH (Sigma). The blots were
developed with fluorochrome-conjugated secondary antibodies
and visualized using the Odyssey infra-red fluorescence imaging
system (LI-COR Biosciences, Lincoln, NE). Band fluorescence
intensities were quantified after background subtraction and used
to calculate the changes in relative amounts of the corresponding
proteins.
Assessment of intestinal inflammation
The colon was excised, its length measured and segments were
placed in tissue culture medium overnight. The culture superna-
tants were then used to estimate the levels of various cytokines by
ELISA, as previously described [8]. The cytokine concentrations
were normalized to the total protein concentration of a
homogenate of the corresponding colon segment and expressed
as ng/mg. In some experiments, colon pro-inflammatory cytokine
expression was assessed by qRT-PCR as described previously
[8,9].
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Huh7 human hepatoma cells [24] were obtained from Dr.
Raymond Chung, Massachusetts General Hospital. The cells were
seeded in 12-well tissue culture plates and treated with various
concentrations of recombinant human TNFa or IL-6 (R&D
Systems) for different time periods. Total RNA was prepared using
TRIzol and used to estimate hepcidin expression by qRT-PCR.
Primers used to amplify human hepcidin were: forward,
59CTCTGTTTTCCCACAACAGAC39, reverse, 59TAGGG-
GAAGTGGGTGTCTC39. Relative expression was calculated
using the 2
2DDCt method after normalizing to actin. In some
experiments, the cells were transiently transfected with a firefly
luciferase reporter driven by the human hepcidin promoter [25]
using Lipofectamine 2000 (Life Technologies, Grand Island, NY),
along with a constitutively expressed Renilla luciferase reporter.
Forty-eight hours after transfection, the cells were treated with
recombinant TNFa. Cell lysates were prepared and used to
estimate firefly luciferase activity normalized to Renilla luciferase
using a Dual-Luciferase kit (Promega, Madison, WI).
In vivo manipulation of TNFa
Non-colitic wild-type mice were injected intraperitoneally with
recombinant TNFa (R&D Systems), either 25 mg/kg body weight
per dose given at time 0 and 2 hours followed by sacrifice at
6 hours, or 50 mg/kg body weight given at time 0 followed by
sacrifice at 16 hours. Control mice were injected with equivalent
volumes of PBS according to the same schedule. Based on earlier
studies of TNFa neutralization in mice [26], we administered the
anti-TNFa antibody infliximab (Remicade, Centocor Ortho
Biotech, Malvern, PA) by intraperitoneal injection at 10 mg/kg
body weight per dose. In the DSS colitis model, the antibody was
injected on alternate days starting on the day DSS was initiated,
resulting in a total of 4 doses by the end of 7 days. Control animals
were injected with an equivalent volume of PBS at the same times
that the anti-TNFa treated mice received the antibody injections.
TNFa neutralization in TRUC mice was carried out as described
previously [23], starting at 4 weeks of age (hamster anti-mouse
TNFa antibody IgG1 clone TN3-19.12 or an isotype-matched
control antibody, both obtained from Bio Express Inc., intraper-
itoneally injected at 15 mg/kg once weekly for 4 weeks). In all
neutralization experiments, the animals were sacrificed one day
after the last dose of antibody.
Statistical analysis
The student’s t test was used to compare results between groups.
A p value of ,0.05 was considered to be statistically significant. In
the figures, statistically significant differences are indicated with an
asterisk. Where the difference is close to significance, the actual p
value is noted.
Results
We showed earlier that liver hepcidin expression increased
during the initial 48 hours of DSS treatment, and that the up-
regulation was dependent on IL-6 [9]. When we extended the time
of DSS treatment, we were surprised to find that hepcidin
expression (as determined by qRT-PCR) was significantly reduced
Figure 1. Alterations of iron metabolism in DSS colitis. A, Hepcidin mRNA levels, normalized to GAPDH, in livers of control, untreated mice
(Con), or mice treated for 3 or 7 days with DSS. Expression is indicated relative to the mean of the control animals. *p=0.01, n=7 mice per group. B,
Serum transaminase levels in control, untreated mice (Con), and mice treated for 7 days with DSS. n=10 for the control group and 8 in the DSS
treated group. C, Splenic iron concentrations in control, untreated mice (Con), or mice treated for 3 or 7 days with DSS. n=7 in each group. D, Serum
iron concentrations in control, untreated mice (Con), or mice treated for 3 or 7 days with DSS. n=4 (control), 5 (3d DSS), 4 (7d DSS).
doi:10.1371/journal.pone.0038136.g001
Colitis-Induced Down-Regulation of Hepcidin
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e38136by 7 days (Figure 1A) and remained at a persistently low level for
as long as 2 weeks (not shown). The reduction of hepcidin
expression was unlikely to be the result of a generalized
impairment of liver function because serum transaminase levels
did not change significantly (Figure 1B). Since an assay to measure
levels of the hepcidin peptide is not generally available, we
determined if the changes in hepcidin mRNA were associated with
alterations in tissue iron distribution. A decrease in hepcidin is
expected to lead to increased ferroportin expression on phagocytes
of the spleen and a consequent efflux of iron from these cells into
the circulation [3]. Accordingly, we measured serum and splenic
iron concentrations. In keeping with the down-regulation of
hepcidin, we found clear trends (p=0.05) towards decreased
splenic iron (Figure 1C) and increased serum iron (Figure 1D) in
the mice with DSS colitis.
To investigate the mechanism of DSS colitis-induced down-
regulation of hepcidin, we considered the possibility that TNFa
might be involved, since expression of this cytokine is elevated in
the colon (Figure S1A) and liver (data not shown) as part of the
inflammatory process. We tested this idea initially in the Huh7
hepatoma cell line, where we were able to demonstrate a dose-
dependent inhibition of hepcidin expression following treatment
with TNFa (Figure 2A). Furthermore, TNFa was able to inhibit
the up-regulation of hepcidin induced by IL-6 in the Huh7 cells
(Figure 2B), which could help to explain why hepcidin expression
was decreased during DSS colitis despite increased levels of IL-6
produced by the colon (Figure S1B). The effect of TNFa was at the
level of transcription, as indicated by transient transfection of
Huh7 cells with a luciferase reporter driven by the hepcidin
promoter (Figure 2C). The TNFa-induced down-regulation of
hepcidin in Huh7 cells was not the result of cytotoxicity as
indicated by a lactate dehydrogenase release assay (Figure S2).
Figure 2. Effects of TNFa on hepcidin expression in Huh7 cells. A, Huh7 cells were treated with the indicated concentrations of TNFa for
12 hours and hepcidin expression, normalized to actin, was determined relative to the mean of untreated cells. *p,0.0001, n=5 for each condition.
B, Huh7 cells were treated for 12 hours with 10 ng/ml of IL-6, either alone or together with 10 ng/ml of TNFa, and hepcidin expression, normalized to
actin, was determined relative to the mean of control, untreated cells. *p=0.014, n=3 for each condition. C, Huh7 cells were transfected with a firefly
luciferase reporter under the control of the hepcidin promoter along with a constitutively expressed Renilla reporter. Forty-eight hours after
transfection, the cells were treated with 10 ng/ml of TNFa for 12 hours and luciferase activities determined. The ratio of firefly to Renilla (F/R)
luciferase activity is indicated. *p=0.002, n=3 for each condition.
doi:10.1371/journal.pone.0038136.g002
Figure 3. Effect of TNFa on hepcidin expression in vivo. Mice
without colitis were treated with PBS or recombinant TNFa (rTNFa) for 6
or 16 hours as described in the text. Liver hepcidin expression was
analyzed and is shown relative to the mean of PBS-treated mice after
normalizing to GAPDH. *p=0.005, n=8 (PBS), 6 (each of the TNFa
treated groups).
doi:10.1371/journal.pone.0038136.g003
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injected wild-type mice without colitis with the recombinant
cytokine and found, consistent with the results in the Huh7 cells,
that hepcidin expression was significantly reduced (Figure 3).
Serum transaminase estimation did not indicate any hepatoxicity
resulting from the TNFa treatment (data not shown). We then
tested the effect of the TNFa neutralizing antibody infliximab in
mice with DSS colitis. The efficacy of neutralization was
confirmed by our finding that the severity of intestinal inflamma-
tion, as indicated by colon length and colon IL-6 levels, was
significantly reduced in the animals treated with infliximab (Figure
S3). In addition, hepcidin expression was significantly elevated in
the infliximab-treated colitic mice (Figure 4A). In aggregate, our
results indicate that hepcidin expression is inhibited during DSS
colitis by a TNFa-dependent mechanism.
We wished to determine whether TNFa-mediated inhibitionof
hepcidin expression was a unique feature of DSS colitis.
Accordingly, we evaluated another model of intestinal inflamma-
tion caused by innate immune activation – spontaneous colitis
occurring in TRUC mice, which have a combined deficiency of
Rag2 and T-bet [23]. The lack of T-bet and lymphocytes in these
animals results in excessive TNFa production by colonic dendritic
cells, with consequent enterocyte apoptosis, colonic barrier
disruption, alterations in the microbiota, and development of a
progressive, TNFa-dependent colitis starting at about 4 weeks of
age. Cohorts of 4 week old TRUC mice were treated for 4 weeks
with weekly injections of a neutralizing hamster anti-mouse TNFa
antibody [23] or an isotype-matched control. Compared to
similarly aged, non-colitic Rag2 knockout mice, the isotype-
treated TRUC mice with colitis displayed a trend (p=0.07)
towards lower hepcidin levels, while anti-TNFa treatment of the
TRUC mice led to a significant increase in hepcidin (Figure 4B).
Thus, our findings demonstrate that TNFa has an inhibitory effect
on hepcidin expression in a second model of innate colitis.
We carried out additional experiments with the DSS colitis
model to further elucidate the mechanism of hepcidin down-
regulation. We focused on the BMP signaling pathway given its
important role in regulation of hepcidin expression [9,20–22]. We
found that hepatic expression of the Smad1 protein, one of the
receptor-associated Smads that transduces signals from the BMP
receptor complex, was decreased significantly in the mice with
DSS colitis (Figure 5). Similar results were obtained with an
antibody recognizing all 3 receptor-associated Smads involved in
BMP signaling, Smads 1, 5 and 8 (Figure S4). Phosphorylation
itself appeared to occur normally, as indicated by a trend towards
an increase in the ratio of phosphorylated to total Smad (Figure 5).
The DSS colitis-induced decrease in Smad1 protein expression
was prevented by TNFa neutralization (Figures 6A and 6B). The
anti-TNFa treatment did not significantly alter levels of the Smad1
mRNA (Figure 6C), suggesting that the effect of TNFa on Smad1
expression was at the level of translation or post-translational
stability. Substantiating the results of the anti-TNFa experiments,
we found that treatment of non-colitic mice with recombinant
TNFa led to a reduction in Smad1 protein levels (Figures 7A and
7B) without significant effects on Smad1 mRNA (Figure 7C).
Moreover, the treatment with TNFa led to a significant decrease
in expression of Id1, a transcriptional target of the BMP/Smad
pathway [22] (Figure S5). Taken together, our findings suggest
that the inhibitory effect of TNFa on hepcidin expression during
DSS colitis is mediated by down-regulation of Smad1 protein (and
possibly Smad5 and Smad8) and consequent interference with
BMP-activated signals.
Discussion
There has been a great deal of interest in understanding how
hepcidin is regulated in IBD because of the role played by this
hormone in the pathogenesis of AI [1,2]. Elucidation of the
mechanisms that lead to hepcidin up-regulation in inflammatory
states such as IBD is an essential first step in the development of
strategies to inhibit this up-regulation and thereby prevent or treat
AI. Earlier experiments from our laboratory have also raised the
possibility that, in addition to its role in AI, hepcidin may
contribute to the inflammatory process itself by increasing intra-
macrophage iron and promoting the production of pro-inflam-
matory cytokines [8,9]. Thus, inhibiting hepcidin expression could
have the dual benefit of helping to correct AI and to ameliorate
inflammation. The work described here, together with our
previously published findings [9], provides important mechanistic
insights into the regulation of hepcidin during intestinal inflam-
mation.
Our earlier experiments demonstrated that hepcidin expression
is increased during multiple forms of intestinal inflammation in
Figure 4. Effect of TNFa neutralization on hepcidin expression
in DSS colitis. A, Mice with DSS-induced colitis were treated with
neutralizing anti-TNFa antibody or vehicle (PBS) as described in the text.
Liver hepcidin expression was analyzed and is shown relative to the
mean of PBS-treated mice after normalizing to GAPDH. *p=0.03, n=5
(PBS), 10 (anti-TNFa). B, TRUC mice were treated with a neutralizing
anti-TNFa antibody or an isotype-matched control antibody as
described in the text. Liver hepcidin levels were measured and is
shown relative to the mean of Rag2 knockout (KO) mice without colitis
after normalizing to GAPDH. *p=0.02, n=4 (Rag2 KO), 5 (TRUC isotype),
5 (TRUC anti-TNFa).
doi:10.1371/journal.pone.0038136.g004
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colitis, piroxicam/IL-10 knockout colitis and T cell transfer colitis,
with BMPs 2, 4 and 6 playing a positive regulatory role in this
process [8,9]. IL-6 had a similar up-regulating effect in early DSS
colitis [9]. Others have demonstrated the up-regulation of
hepcidin in human and murine malaria, BMP- and IL-6-
dependent in the latter, and a TLR2-dependent, IL-6-independent
increase in Borrelia infection of mice [27–30]. Among these
examples of in vivo inflammation, murine malaria (ref. 29) and
DSS and TRUC colitis (the present work) appear to be unique in
manifesting decreased expression of hepcidin in the later stages of
the inflammatory process. Our findings have shed light on the
mechanism of hepcidin down-regulation in the latter models by
implicating TNFa. Although TNFa has been shown previously to
inhibit hepcidin expression in a hepatocyte cell line [15], the
results shown here represent, to the best of our knowledge, the first
demonstration that this cytokine has a negative regulatory effect
on hepcidin in clinically relevant in vivo models of inflammation.
The mechanism by which TNFa inhibits hepcidin expression
appears to involve decreased expression of the Smad1 protein
(possibly together with Smad 5 and Smad8), an essential
component of the machinery that transduces the BMP-induced
signals required for hepcidin expression [22]. TNFa did not alter
expression of the Smad1 mRNA, suggesting that the effect was at
the level of translation or post-translational stability. The Smad1
protein has been shown to be regulated by proteasomal
degradation following sequential phosphorylation of the carboxy-
terminus by mitogen-activated protein kinases and glycogen
synthase kinase 3 [31]. Further studies will be required to
determine whether this mechanism might explain the effect of
TNFa on Smad1 expression, and whether the decrease in Smad1
expression is sufficient to explain TNFa-induced down-regulation
of hepcidin. TNFa has been reported to have other effects on the
BMP signaling pathway, including induction of the inhibitor
Smad7, repression of BMP4 and the co-receptor hemojuvelin,
induction of the ubiquitin ligase Smurf1, and interference with the
binding of Smad1-Smad4 complexes to their target DNA [32–36].
It is possible that such effects may also contribute to TNFa-
induced down-regulation of hepcidin, and additional experiments
will be required to clarify this issue in a definitive fashion.
Despite the clear involvement of TNFa in regulation of
hepcidin expression in DSS colitis and TRUC colitis, we found
that neutralization of the cytokine had no effect on hepcidin
expression in the spontaneous T cell-mediated intestinal inflam-
mation that occurs in mice with hematopoietic- and endothelial-
specific deficiency of the av integrin [37] (data not shown). TNFa
Figure 5. Alterations in the BMP/Smad pathway in DSS colitis. A, Representative immunoblotting of liver lysates for phosphorylated Smad
(pSmad) 1/5/8, total Smad1 and actin in control untreated mice (Con), or mice treated for 3 or 7 days with DSS. Each lane represents an individual
animal. B, Quantitation of band intensities from the immunoblotting experiment. *p=0.001, **p=0.001, n=6 mice per group.
doi:10.1371/journal.pone.0038136.g005
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indeed anti-TNFa treatment attenuates the severity of the colitis in
the av integrin knockout mice. Therefore, the failure of TNFa
neutralization to alter hepcidin expression in these animals raises
the possibility that TNFa-dependent down-regulation of hepcidin
may be counteracted by other factors during T cell-mediated
intestinal inflammation. Although the identity and mechanism of
action of such factors awaits elucidation, this idea would be
consistent with our earlier observations demonstrating increased
hepcidin expression in mice with piroxicam/IL-10 knockout colitis
and T cell transfer colitis [8,9], as well as with the results of those
studies of human IBD that demonstrate elevated hepcidin levels
[5,6]. Taken together, these observations suggest that the
regulation of hepcidin expression may vary depending on the
type of intestinal inflammation being considered, and that net
hepcidin expression may be determined by whether positive or
negative influences dominate. Such variations may contribute to
the inconsistencies in hepcidin levels that have been noted in
studies of human IBD. Detailed characterization of the factors that
regulate hepcidin expression in different forms of intestinal
inflammation will be required in order to develop rational
strategies for the therapeutic modulation of hepcidin in IBD.
Our experiments have revealed a previously unappreciated role
for TNFa in the down-regulation of hepcidin expression in at least
some forms of intestinal inflammation. This function may be
important in helping to maintain serum iron levels in the face of
inflammatory insults. It is also possible that TNFa-induced down-
regulation of hepcidin may have evolved as a mechanism to
protect against intracellular pathogens. Several studies have shown
that hepcidin-dependent changes in the levels of ferroportin
expressed by macrophages have a significant influence on the
growth of pathogens that reside in these cells, such as Salmonella,
Chlamydia and Mycobacteria [38–40]. By decreasing the amount of
hepcidin produced by the liver, TNFa would allow ferroportin
expression on macrophages to go up, thereby increasing iron efflux
from these cells and depriving any intracellular pathogens of this
essential nutrient. Given the importance of TNFa in IBD
pathogenesis, the increasing use of anti-TNFa therapy to control
the disease, and the risk of tuberculosis associated with such
therapy [41], it will be important to determine if TNFa has
inhibitory effects on hepcidin expression in human IBD.
Figure 6. Effects of TNFa neutralization on the BMP/Smad pathway in DSS colitis. A, Representative immunoblotting of liver lysates for
phosphorylated Smad (pSmad) 1/5/8, total Smad1 and actin in mice with DSS colitis that were treated with anti-TNFa or vehicle (PBS) for 7 days. Each
lane represents an individual animal. B, Quantitation of band intensities from immunoblotting experiment. *p=0.05, **p=0.02, ***p=0.02, n=5
(PBS), 10 (anti-TNFa). C, Smad1 mRNA expression in mice with DSS colitis that were treated with anti-TNFa or vehicle (PBS) for 7 days, shown relative
to the mean of PBS-treated mice after normalizing to GAPDH. n=5 (PBS), 10 (anti-TNFa).
doi:10.1371/journal.pone.0038136.g006
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Figure S1 TNFa expression during DSS colitis. A, TNFa
secreted by colon explants from control, untreated mice (Con), or
mice treated for 3 or 7 days with DSS. *p=0.03, **p=0.005,
n=10 for control group, 9 for each of the DSS-treated groups. B,
IL-6 secreted by colon explants from control, untreated mice
(Con), or mice treated for 3 or 7 days with DSS. *p=0.0001,
n=10 for control and 3-day DSS treated groups, 9 for the 7-day
DSS treated group.
(PDF)
Figure S2 Effect of TNFa on lactate dehydrogenase
(LDH) release in Huh7 cells. Huh7 cells were treated with
10 ng/ml of TNFa for 12 hours. LDH released into the
supernatant was measured using the CytoTox96 kit (Promega,
Madison, WI) and expressed as a percentage of the amount in the
cell lysate.
(PDF)
Figure S3 Effects of TNFa neutralization on DSS colitis.
Colon length (A) and colon IL-6 secretion (B) were measured
following 7 days of DSS treatment during which the mice were
injected with PBS or anti-TNFa.I nA, * p=0.001, n=5 (control),
10 (anti-TNFa). In B, *p=0.05, n=5 (control), 10 (anti-TNFa).
(PDF)
Figure S4 Alterations in Smad1/5/8 expression during
DSS colitis A, Immunoblotting of liver lysates for total Smad1/
5/8 and actin in control, untreated mice (Con), or mice treated for
3 or 7 days with DSS. Each lane represents an individual animal.
B, Quantitation of band intensities from the immunoblotting
experiment. *p=0.047, n=3 in each group.
(PDF)
Figure S5 Effect of TNFa on Id1 expression in vivo. Liver
Id1 mRNA levels in control (Con) mice, or mice treated with
recombinant TNFa (rTNFa)5 0mg/kg body weight followed by
sacrifice 16 hours later. Id1 expression is shown relative to the
mean of the controls after normalizing to GAPDH. *p=0.011,
n=5 in each group.
(PDF)
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Figure 7. Effects of recombinant TNFa on the BMP/Smad pathway in non-colitic mice. A, Immunoblotting of liver lysates for total Smad1
and GAPDH in non-colitic mice treated with PBS or 50 mg/kg body weight recombinant TNFa (rTNFa) followed by sacrifice 16 hours later. Each lane
represents an individual mouse. The lanes with the lysates from the rTNFa-treated mice have been over-loaded to clearly illustrate the decrease in
Smad1 levels. B, Quantitation of band intensities from immunoblotting. *p=0.0001, **p=0.0004, ***p=0.01, n=3 mice per group. C, Liver Smad1
mRNA levels in the non-colitic mice treated with PBS or rTNFa, shown relative to the mean of PBS-treated mice after normalizing to GAPDH. n=8
(control), 6 (rTNFa).
doi:10.1371/journal.pone.0038136.g007
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